Literature DB >> 14747663

Energy homeostasis, obesity and eating disorders: recent advances in endocrinology.

Susan M Gale1, V Daniel Castracane, Christos S Mantzoros.   

Abstract

Health problems resulting from obesity could offset many of the recent health gains achieved by modern medicine, and obesity may replace tobacco as the number one health risk for developed societies. An estimated 300,000 deaths per year and significant morbidity are directly attributable to obesity, mainly due to heart disease, diabetes, cancer, asthma, sleep apnea, arthritis, reproductive complications and psychological disturbances. In parallel with the increasing prevalence of obesity, there has been a dramatic increase in the number of scientific and clinical studies on the control of energy homeostasis and the pathogenesis of obesity to further our understanding of energy balance. It is now recognized that there are many central and peripheral factors involved in energy homeostasis, and it is expected that the understanding of these mechanisms should lead to effective treatments for the control of obesity. This brief review discusses the potential role of several recently discovered molecular pathways involved in the control of energy homeostasis, obesity and eating disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747663     DOI: 10.1093/jn/134.2.295

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  55 in total

Review 1.  Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds.

Authors:  Konstantinos Michalakis; Carel le Roux
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

Review 2.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

3.  Plasma leptin and ghrelin concentrations in patients with Crohn's disease.

Authors:  Yoshito Nishi; Hajime Isomoto; Hiroaki Ueno; Ken Ohnita; Chun Yang Wen; Fuminao Takeshima; Ryosuke Mishima; Masamitsu Nakazato; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 4.  The metabolic consequences of sleep deprivation.

Authors:  Kristen L Knutson; Karine Spiegel; Plamen Penev; Eve Van Cauter
Journal:  Sleep Med Rev       Date:  2007-04-17       Impact factor: 11.609

Review 5.  Associations between sleep loss and increased risk of obesity and diabetes.

Authors:  Kristen L Knutson; Eve Van Cauter
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 6.  Problems associated with short sleep: bridging the gap between laboratory and epidemiological studies.

Authors:  Michael A Grandner; Nirav P Patel; Philip R Gehrman; Michael L Perlis; Allan I Pack
Journal:  Sleep Med Rev       Date:  2009-11-06       Impact factor: 11.609

7.  Ghrelin and apolipoprotein AIV levels show opposite trends to leptin levels during weight loss in morbidly obese patients.

Authors:  E Pardina; M D López-Tejero; R Llamas; R Catalán; R Galard; H Allende; V Vargas; A Lecube; J M Fort; J A Baena-Fustegueras; J Peinado-Onsurbe
Journal:  Obes Surg       Date:  2009-01-27       Impact factor: 4.129

8.  Tolerance and efficacy of an air-filled balloon in non-morbidly obese patients: results of a prospective multicenter study.

Authors:  François Mion; Rodica Gincul; Sabine Roman; Sylvain Beorchia; Frank Hedelius; Nicolas Claudel; Roger-Michel Bory; Etienne Malvoisin; Frédérique Trepo; Bertrand Napoleon
Journal:  Obes Surg       Date:  2007-06       Impact factor: 4.129

9.  Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.

Authors:  Brian Bostick; Javad Habibi; Lixin Ma; Annayya Aroor; Nathan Rehmer; Melvin R Hayden; James R Sowers
Journal:  Metabolism       Date:  2014-04-12       Impact factor: 8.694

Review 10.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.